Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results

– Second Quarter 2023 Total Revenue of $38.3 Million; Net Product Revenue for QINLOCK® (ripretinib) Increased 18% to $37.3 Million Compared to Second Quarter 2022 –– Top-line Results for MOTION Pivotal Phase 3 Study of Vimseltinib Expected in Fourth Quarter 2023 –– INSIGHT Pivotal Phase 3 Study of QINLOCK in Second-...

Related Keywords

Italy ,Switzerland ,Israel ,Australia ,New Zealand ,Canada ,China ,United States ,Taiwan ,Waltham ,Leicestershire ,United Kingdom ,Macau ,Hong Kong ,Singapore ,Canadian ,American ,Daniell Flynn ,Dan Flynn ,Jamesa Bristol ,Maghan Meyers ,Steve Hoerter ,Dashyant Dhanak ,David Rosen ,Pfizer Inc ,Deciphera Pharmaceuticals Inc ,Research Engine ,Exchange Commission ,Pfizer ,Deciphera Pharmaceuticals ,American Association For Cancer ,Linkedin ,American Society Of Clinical Oncology ,Nasdaq ,Incyte Corporation ,Company Founder ,Chairperson Or Co ,Canadian Pharmaceutical Alliance ,Zai Lab ,Drug Administration ,European Union ,Second Quarter ,Net Product Revenue ,Top Line Results ,Vimseltinib Expected ,Fourth Quarter ,First Sites Open ,Escalation Cohorts ,Cetuximab Initiated ,First Site Open ,Combination Dose Escalation Cohorts ,Inhibitors Ongoing ,Chief Executive Officer ,Investigational New Drug ,Dash Dhanak ,Chief Scientific Officer ,Clinical Oncology ,Annual Meeting ,Series Session ,American Association ,Executive Vice President ,Senior Advisor ,Ron Squarer ,Private Securities Litigation Reform Act ,Quarterly Report ,Months Ended June ,